• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡萄糖激酶、葡萄糖稳态与糖尿病

Glucokinase, glucose homeostasis, and diabetes mellitus.

作者信息

Matschinsky Franz M

机构信息

University of Pennsylvania Medical School, Department of Biochemistry and Biophysics, 501 Stemmler Hall, 36th & Hamilton Walk, Philadelphia, PA 19104, USA.

出版信息

Curr Diab Rep. 2005 Jun;5(3):171-6. doi: 10.1007/s11892-005-0005-4.

DOI:10.1007/s11892-005-0005-4
PMID:15929862
Abstract

The enzyme glucokinase (GK) regulates the rate of glucose metabolism in many tissues, including liver, the pancreatic b cells, certain neurons, enteroendocrine cells, and the pituitary, serving as a glucose sensor in many of these. Thus, GK plays a critical role in glucose homeostasis. Spontaneous mutants of GK in humans result in autosomal-dominant hypo- and hyperglycemia syndromes described as "GK disease." GK activator drugs have been discovered that lower blood glucose in normal and diabetic animals and promise to be useful in the treatment of type 2 diabetes mellitus. There is no question that the GK molecule and related issues will continue to be a fruitful topic for future research.

摘要

葡萄糖激酶(GK)在包括肝脏、胰腺β细胞、某些神经元、肠内分泌细胞和垂体在内的许多组织中调节葡萄糖代谢速率,在其中许多组织中充当葡萄糖传感器。因此,GK在葡萄糖稳态中起关键作用。人类GK的自发突变会导致常染色体显性低血糖和高血糖综合征,称为“GK疾病”。已发现GK激活剂药物可降低正常和糖尿病动物的血糖,并有望用于治疗2型糖尿病。毫无疑问,GK分子及相关问题将继续成为未来研究的一个富有成果的主题。

相似文献

1
Glucokinase, glucose homeostasis, and diabetes mellitus.葡萄糖激酶、葡萄糖稳态与糖尿病
Curr Diab Rep. 2005 Jun;5(3):171-6. doi: 10.1007/s11892-005-0005-4.
2
Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.用于糖尿病治疗的葡萄糖激酶激活剂的研发:理论与实践层面
Handb Exp Pharmacol. 2011(203):357-401. doi: 10.1007/978-3-642-17214-4_15.
3
Small molecule glucokinase activators as novel anti-diabetic agents.小分子葡萄糖激酶激活剂作为新型抗糖尿病药物。
Biochem Soc Trans. 2005 Apr;33(Pt 2):371-4. doi: 10.1042/BST0330371.
4
Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus.用于治疗2型糖尿病的葡萄糖激酶激活剂和葡萄糖激酶调节蛋白破坏剂的最新进展
Curr Diabetes Rev. 2019;15(3):205-212. doi: 10.2174/1573399814666180724100749.
5
Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes.葡萄糖激酶激活剂在糖尿病葡萄糖稳态恢复中的临床研究。
J Diabetes. 2024 May;16(5):e13544. doi: 10.1111/1753-0407.13544.
6
Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.作为降血糖药物的小分子葡萄糖激酶激活剂:糖尿病治疗的新范例
Curr Med Chem. 2006;13(15):1839-43. doi: 10.2174/092986706777452551.
7
Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.用于治疗2型糖尿病的葡萄糖激酶激活剂的最新进展。
Mini Rev Med Chem. 2014;14(7):585-602. doi: 10.2174/1389557514666140722082713.
8
Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.最近葡萄糖激酶激活剂在 2 型糖尿病治疗中的临床进展。
Pharmazie. 2020 Jun 1;75(6):230-235. doi: 10.1691/ph.2020.0409.
9
Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.用于治疗2型糖尿病的新型高效全身性葡萄糖激酶激活剂。
Bioorg Med Chem Lett. 2017 May 1;27(9):2069-2073. doi: 10.1016/j.bmcl.2016.10.085. Epub 2016 Oct 31.
10
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.葡萄糖激酶调节蛋白小分子抑制剂的抗糖尿病作用。
Nature. 2013 Dec 19;504(7480):437-40. doi: 10.1038/nature12724. Epub 2013 Nov 13.

引用本文的文献

1
Roles of β-Cell Hypoxia in the Progression of Type 2 Diabetes.β细胞缺氧在2型糖尿病进展中的作用
Int J Mol Sci. 2024 Apr 10;25(8):4186. doi: 10.3390/ijms25084186.
2
Genetic perspectives on childhood monogenic diabetes: Diagnosis, management, and future directions.儿童单基因糖尿病的遗传学观点:诊断、管理及未来方向
World J Diabetes. 2023 Dec 15;14(12):1738-1753. doi: 10.4239/wjd.v14.i12.1738.
3
Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China.

本文引用的文献

1
Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young.来自一个导致青年发病型成年糖尿病的新型突变(V62M)对葡萄糖激酶结构与调控的见解。
J Biol Chem. 2005 Apr 8;280(14):14105-13. doi: 10.1074/jbc.M413146200. Epub 2005 Jan 25.
2
Glucokinase and glucose homeostasis: proven concepts and new ideas.葡萄糖激酶与葡萄糖稳态:已证实的概念与新观点。
Biochem Soc Trans. 2005 Feb;33(Pt 1):306-10. doi: 10.1042/BST0330306.
3
A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene.
健康志愿者和 2 型糖尿病患者中美格列奈酶激动剂 PB201 的群体药代动力学/药效学分析:促进 PB201 在华的临床开发。
Clin Pharmacokinet. 2024 Jan;63(1):93-108. doi: 10.1007/s40262-023-01321-8. Epub 2023 Nov 20.
4
Proteomics identifies the developmental regulation of HKDC1 in liver of pigs and mice.蛋白质组学鉴定了 HKDC1 在猪和鼠肝脏中的发育调控作用。
Am J Physiol Regul Integr Comp Physiol. 2023 Oct 1;325(4):R389-R400. doi: 10.1152/ajpregu.00253.2022. Epub 2023 Aug 7.
5
The genetic polymorphisms Associated with type 2 diabetes Mellitus.与2型糖尿病相关的基因多态性
Indian J Clin Biochem. 2023 Jul;38(3):385-392. doi: 10.1007/s12291-022-01057-5. Epub 2022 Aug 10.
6
Aiding Cancer's "Sweet Tooth": Role of Hexokinases in Metabolic Reprogramming.助力癌症的“嗜甜癖”:己糖激酶在代谢重编程中的作用
Life (Basel). 2023 Apr 4;13(4):946. doi: 10.3390/life13040946.
7
A systematic analysis of anti-diabetic medicinal plants from cells to clinical trials.从细胞到临床试验的抗糖尿病药用植物系统分析。
PeerJ. 2023 Jan 5;11:e14639. doi: 10.7717/peerj.14639. eCollection 2023.
8
ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents.《国际儿童青少年糖尿病研究学会(ISPAD)2022年临床实践共识指南:儿童和青少年单基因糖尿病的诊断与管理》
Pediatr Diabetes. 2022 Dec;23(8):1188-1211. doi: 10.1111/pedi.13426.
9
Influence of biotin intervention on glycemic control and lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.生物素干预对2型糖尿病患者血糖控制和血脂水平的影响:一项系统评价和荟萃分析。
Front Nutr. 2022 Oct 31;9:1046800. doi: 10.3389/fnut.2022.1046800. eCollection 2022.
10
Identification of missense SNP-mediated mutations in the regulatory sites of aldose reductase (ALR2) responsible for treatment failure in diabetic complications.鉴定醛糖还原酶(ALR2)调控位点错义 SNP 介导的突变,该突变与糖尿病并发症治疗失败有关。
J Mol Model. 2022 Aug 19;28(9):260. doi: 10.1007/s00894-022-05256-y.
一种由N-亚硝基脲诱变产生的2型糖尿病新小鼠模型,是葡萄糖激酶基因错义突变的结果。
Diabetes. 2004 Jun;53(6):1577-83. doi: 10.2337/diabetes.53.6.1577.
4
A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program.通过大规模ENU诱变程序产生的一系列成年发病的2型青少年发病型糖尿病(MODY2)小鼠模型。
Hum Mol Genet. 2004 Jun 1;13(11):1147-57. doi: 10.1093/hmg/ddh133. Epub 2004 Apr 21.
5
Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.单体变构酶人类葡萄糖激酶变构调节的结构基础。
Structure. 2004 Mar;12(3):429-38. doi: 10.1016/j.str.2004.02.005.
6
Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators.新型小分子葡萄糖激酶激活剂对肝细胞葡萄糖代谢的刺激作用。
Diabetes. 2004 Mar;53(3):535-41. doi: 10.2337/diabetes.53.3.535.
7
Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.高血糖和低血糖中的葡萄糖激酶(GCK)突变:青少年发病的成年型糖尿病、永久性新生儿糖尿病和婴儿高胰岛素血症。
Hum Mutat. 2003 Nov;22(5):353-62. doi: 10.1002/humu.10277.
8
Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations.从自然发生的低血糖突变深入了解葡萄糖激酶激活的生化和遗传基础。
Diabetes. 2003 Sep;52(9):2433-40. doi: 10.2337/diabetes.52.9.2433.
9
BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis.BAD与葡萄糖激酶存在于一个整合糖酵解与细胞凋亡的线粒体复合体中。
Nature. 2003 Aug 21;424(6951):952-6. doi: 10.1038/nature01825.
10
Allosteric activators of glucokinase: potential role in diabetes therapy.葡萄糖激酶的变构激活剂:在糖尿病治疗中的潜在作用。
Science. 2003 Jul 18;301(5631):370-3. doi: 10.1126/science.1084073.